CLINICAL CHARACTERISTICS AND PREDICTIVE FACTORS OF TREATMENT RESPONSE IN MIGRAINE HEADACHE AT TAM ANH GENERAL HOSPITAL IN HO CHI MINH CITY

Thị Minh Đức Nguyễn1, , Nguyễn Uyên Dung Trần1, Phạm Thùy Linh Võ1, Thị Kim Ngân Lý1
1 Bệnh viện Đa khoa Tâm Anh TP. HCM

Main Article Content

Abstract

Background: Migraine is a common primary headache disorder that significantly affects quality of life and work productivity. Identifying clinical features and factors associated with treatment response is essential for optimizing preventive therapy.


Objectives: To describe demographic and clinical characteristics, comorbid conditions, and the effectiveness of preventive migraine treatment; to examine the associations between comorbidities and these factors; and to identify predictors of response to preventive therapy in patients with migraine at Tam Anh General Hospital, Ho Chi Minh City.


Results: The mean age was 38 ± 17 years, with a female predominance (79.4%). Unilateral headache (59.1%), pulsating pain (49.4%), and moderate intensity (65.9%) were the most common clinical features. Nausea was the most frequent associated symptom (53.3%). Sleep disorders (23.3%) and anxiety disorders (15.1%) were the most common comorbidities. Topiramate was the most frequently prescribed preventive medication (72.9%). Overall, 87.3% of patients achieved fair-to-good treatment response. Flunarizine demonstrated the highest rate of good/fair response (72.0%). Comorbid conditions were significantly associated with severe pain intensity, atypical pain characteristics, and the presence of sensory symptoms. Multivariate logistic regression identified depression (OR = 0.07), anxiety (OR = 0.36), nausea, vomiting, photophobia, and phonophobia as independent predictors of poor treatment response.


Conclusion: Migraine exhibits heterogeneous clinical manifestations and is frequently associated with psychiatric comorbidities. These comorbidities may substantially affect the response to preventive therapy and should therefore be carefully evaluated and comprehensively managed in clinical practice.

Article Details

References

1. Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021-1039.
2. Ashina M., Hansen J. M., Do T. P. et al, 2019, ‘Migraine and the trigeminovascular system—40 years and counting’, The Lancet Neurology, 18, 8, 795-804
3. Buse D. C., 2023, ‘Psychiatric comorbidities of migraine and their impact on treatment outcomes’, J Neurol, 260(8), 1960–1969.
4. Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A; on behalf of the American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache. 2024;64(4):333-341.
5. Iyengar S., Johnson K. W. and Ossipov M. H. et al, 2019, ‘CGRP and the trigeminal system in migraine’, Headache: The Journal of Head and Face Pain, 59(5), 659-681.
6. Lipton R. B., 2011, ‘Migraine prevalence, disease burden, and the need for preventive therapy’, Neurology.
7. Park J.H., Lee H.J. and Kim J.W. et al, 2021, ‘Prescription patterns for migraine prophylaxis in Korea: a real-world practice analysis’, Korean J Clin Pharmacol., 31(1), 35–44.
8. Vos T., Lim S. S. and Abbafati C. et al, 2020, ‘GBD 2019 diseases and injuries collaborators’, Global burden of, 369, 1990-2019.